Drugs that contain Gabapentin
1. Gralise patents expiration
GRALISE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6340475 | ALMATICA | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(7 years ago) | |
| US6635280 | ALMATICA | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(7 years ago) | |
| US6488962 | ALMATICA | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
Jun, 2020
(3 years ago) | |
| US6723340 | ALMATICA | Optimal polymer mixtures for gastric retentive tablets |
Oct, 2021
(2 years ago) | |
| US8333992 | ALMATICA | Gastric retained gabapentin dosage form |
Oct, 2022
(1 year, 5 months ago) | |
| US8252332 | ALMATICA | Gastric retained gabapentin dosage form |
Oct, 2022
(1 year, 5 months ago) | |
| US7731989 | ALMATICA | Gastric retained gabapentin dosage form |
Oct, 2022
(1 year, 5 months ago) | |
| US8192756 | ALMATICA | Gastric retained gabapentin dosage form |
Oct, 2022
(1 year, 5 months ago) | |
| US7438927 | ALMATICA | Methods of treatment using a gastric retained gabapentin dosage |
Feb, 2024
(a month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jan 28, 2018 |
| Orphan Drug Exclusivity(ODE-6) | Jan 28, 2018 |
| New Product(NP) | Jan 28, 2014 |
Market Authorisation Date: 28 January, 2011
Treatment: Treatment with gabapentin, including treatment of neuropathic pain, including neuropathic pain associated with postherpetic neuralgia
Dosage: TABLET;ORAL
How can I launch a generic of GRALISE before it's drug patent expiration?
More Information on Dosage
GRALISE family patents
2. Neurontin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6054482 | VIATRIS | Lactam-free amino acids |
Apr, 2017
(7 years ago) | |
|
US6054482 (Pediatric) | VIATRIS | Lactam-free amino acids |
Oct, 2017
(6 years ago) | |
| US7256216 | VIATRIS | Liquid pharmaceutical compositions |
May, 2022
(1 year, 10 months ago) | |
|
US7256216 (Pediatric) | VIATRIS | Liquid pharmaceutical compositions |
Nov, 2022
(1 year, 4 months ago) | |
Market Authorisation Date: 30 December, 1993
Treatment: NA
Dosage: CAPSULE;ORAL; TABLET;ORAL; SOLUTION;ORAL
How can I launch a generic of NEURONTIN before it's drug patent expiration?
More Information on Dosage
NEURONTIN family patents